Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer

@article{Temming2017RiskadaptedRS,
  title={Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer},
  author={Susanne Temming and Martin Kocher and Erich Stoelben and Lars Hagmeyer and De-Hua Chang and K. Frank and Khosro Hekmat and J{\"u}rgen Wolf and Wolfgang W Baus and Robert Semrau and Christian Baues and Simone Marnitz},
  journal={Strahlentherapie und Onkologie},
  year={2017},
  volume={194},
  pages={91-97}
}
To evaluate efficacy and toxicity of stereotactic body radiation therapy (SBRT) with CyberKnife® (Accuray, Sunnyvale, CA, USA) in a selected cohort of primary, medically inoperable early-stage non-small cell lung cancer (NSCLC) patients. From 2012 to 2016, 106 patients (median age 74 years, range 50–94 years) with primary NSCLC were treated with SBRT using CyberKnife®. Histologic confirmation was available in 87 patients (82%). For mediastinal staging, 92 patients (87%) underwent 18F… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2016
View 2 Excerpts

SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • 2016

Similar Papers

Loading similar papers…